This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tascilar, M. Articles by Sleijfer, S. Search for Related Content PubMed PubMed Citation Articles by Tascilar, M. Articles by Sleijfer, S.

Sarcoma Research Series

The Pharmacologic Basis of Ifosfamide Use in Adult Patients with Advanced Soft Tissue Sarcomas

Department of Medical Oncology, Erasmus University Medical Center Rotterdam-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

Key Words. Soft tissue sarcoma • Ifosfamide • Pharmacology • Chemotherapy • Pharmacokinetics • Adults

Correspondence: Stefan Sleijfer, M.D., Ph.D., Department of Medical Oncology, Erasmus University Medical Center Rotterdam-Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075EA Rotterdam, The Netherlands. Telephone: 31-0-10-4391733; Fax: 31-0-10-4391003; e-mail: s.sleijfer{at}erasmusmc.nl

Disclosure: No potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.

The treatment outcome of patients with locally advanced and metastatic soft tissue sarcomas is poor. Doxorubicin is regarded as standard treatment, but its use is featured by the occurrence of cardiotoxicity. This hinders the administration of this drug at high doses or in combination with, in theory, attractive newly developed targeted drugs, such as vascular endothelial growth factor (VEGF) pathway inhibitors. The combination of doxorubicin and VEGF pathway inhibitors has been shown to yield an unacceptable high rate of cardiomyopathy. Ifosfamide is the only drug that consistently shows response rates comparable to those of doxorubicin. The lack of cardiotoxicity renders this drug a much more attractive alternative than doxorubicin to be explored at high doses or as part of new drug combinations. This review addresses the clinical pharmacology, metabolism, and present role of ifosfamide in the treatment of locally advanced and/or metastatic soft tissue sarcomas, excluding gastrointestinal stromal tumors, the Ewing-like sarcomas, and other small blue round cell tumors. Furthermore, this review focuses on the anticipated growing role of ifosfamide in the development of new treatment strategies.

This article has been cited by other articles:

				S. Sleijfer, I. Ray-Coquard, Z. Papai, A. Le Cesne, M. Scurr, P. Schoffski, F. Collin, L. Pandite, S. Marreaud, A. De Brauwer, et al. Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043) J. Clin. Oncol., July 1, 2009; 27(19): 3126 - 3132. [Abstract] [Full Text] [PDF]

				S. Sleijfer, W. T.A. van der Graaf, and J.-Y. Blay Angiogenesis Inhibition in Non-GIST Soft Tissue Sarcomas Oncologist, November 1, 2008; 13(11): 1193 - 1200. [Abstract] [Full Text] [PDF]